http://www.lctglobal.com/upload/news...ecruitment.pdf

Parkinson's trial resumes patient recruitment

Living Cell Technologies Limited has received the necessary regulatory approval to resume recruitment of the remaining three patients in the Phase I/IIa clinical trial of NTCELL® in Parkinson’s disease. The trial was paused in December last year while the company completed internal and external audit and regulatory processes.


Dr Ken Taylor, NTCELL Program Director and Acting Chief Executive, is pleased that patient recruitment in the clinical trial of NTCELL for Parkinson’s can resume.


“The completion of the clinical trial is an initial step in progressing NTCELL to commercialisation as the first disease modifying treatment for Parkinson’s disease.”

Living Cell Technologies Limited today announced the placement of 49,410,392 fully paid Ordinary shares at $0.0608 to eligible persons resident in New Zealand, raising $3m. The issue price is a 10% discount to the 5 day volume weighted average closing price to 3 October 2014.

The funds will be used for working capital to continue clinical trials of lead product NTCELL® in Parkinson’s disease and further develop it for other indications.

http://www.scoop.co.nz/stories/BU141...nt-and-spp.htm